Tom 14, Nr 1 (2019)
Artykuł przeglądowy
Opublikowany online: 2018-09-05
Nowe markery biologiczne w kardiologii — czy to właściwy trop?
Folia Cardiologica 2019;14(1):52-59.
Streszczenie
Istnieje wiele markerów oceny ryzyka chorób sercowo-naczyniowych (CVD). Wciąż poszukuje się nowych czułych i spe- cyficznych biomarkerów, które mogłyby pomóc w stratyfikacji ryzyka zarówno wśród populacji zdrowej, jak i obciążonej CVD. Galektyna 3 oraz białko ST-2 wydają się niezwykle obiecującymi wskaźnikami, niemniej potrzebne są dalsze ba- dania nad tymi cząsteczkami, aby poznać ich pełną wartość diagnostyczno-prognostyczną. W artykule zaprezentowano badania i publikacje przedstawiające możliwość wszechstronnego wykorzystania obu biomarkerów, zwłaszcza w cho- robie wieńcowej. Galektyna-3 oraz białko ST-2, dzięki związkowi z procesami włóknienia, mogą się okazać kluczowymi markerami u pacjentów z chorobą wieńcową oraz po zawale serca.
Słowa kluczowe: białko ST-2choroby układu sercowo-naczyniowegochoroba wieńcowagalektyna 3remodelingzawał serca
Referencje
- Gierczyński J, Gryglewicz J, Karczewicz E, Zalewska H. Niewydolność serca — analiza kosztów ekonomicznych i społecznych. Uczelnia Łazarskiego, Warszawa 2013.
- Ciccone MM, Scicchitano P, Zito A, et al. Correlation between coronary artery disease severity, left ventricular mass index and carotid intima media thickness, assessed by radio-frequency. Cardiovasc Ultrasound. 2011; 9: 32.
- Ibanez B, James S, Agewall S, et al. ESC Scientific Document Group . 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39(2): 119–177.
- Yang RiY, Rabinovich GA, Liu FT. Galectins: structure, function and therapeutic potential. Expert Rev Mol Med. 2008; 10: e17.
- Ho JE, Liu C, Lyass A, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol. 2012; 60(14): 1249–1256.
- Barboni EA, Bawumia S, Henrick K, et al. Molecular modeling and mutagenesis studies of the N-terminal domains of galectin-3: evidence for participation with the C-terminal carbohydrate recognition domain in oligosaccharide binding. Glycobiology. 2000; 10(11): 1201–1208.
- Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov. 2008; 7(10): 827–840.
- Shimpo M, Morrow DA, Weinberg EO, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002; 106(23): 2961–2966.
- Meijers WC, van der Velde AR, Pascual-Figal DA, et al. Galectin-3 and post-myocardial infarction cardiac remodeling. Eur J Pharmacol. 2015; 763(Pt A): 115–121.
- Gierlotka M, Zdrojewski T, Wojtyniak B, et al. Incidence, treatment, in-hospital mortality and one-year outcomes of acute myocardial infarction in Poland in 2009-2012--nationwide AMI-PL database. Kardiol Pol. 2015; 73(3): 142–158.
- Papaspyridonos M, McNeill E, de Bono JP, et al. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol. 2008; 28(3): 433–440.
- Iacobini C, Menini S, Ricci C, et al. Advanced lipoxidation end-products mediate lipid-induced glomerular injury: role of receptor-mediated mechanisms. J Pathol. 2009; 218(3): 360–369.
- MacKinnon AC, Liu X, Hadoke PWf, et al. Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice. Glycobiology. 2013; 23(6): 654–663.
- Sanchez-Mas J, Lax A, Asensio-Lopez MC, et al. Galectin-3 expression in cardiac remodeling after myocardial infarction. Int J Cardiol. 2014; 172(1): e98–e9e101.
- González GE, Cassaglia P, Noli Truant S, et al. Galectin-3 is essential for early wound healing and ventricular remodeling after myocardial infarction in mice. Int J Cardiol. 2014; 176(3): 1423–1425.
- Tsai TH, Sung PH, Chang LT, et al. Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention. J Atheroscler Thromb. 2012; 19(12): 1073–1082.
- Gullestad L, Ueland T, Kjekshus J, et al. CORONA Study Group. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J. 2012; 33(18): 2290–2296.
- Szadkowska I, Wlazeł RN, Migała M, et al. The association between galectin-3 and clinical parameters in patients with first acute myocardial infarction treated with primary percutaneous coronary angioplasty. Cardiol J. 2013; 20(6): 577–582.
- Weir RAP, Petrie C, Murphy C, et al. Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circ Heart Fail. 2013; 6(3): 492–498.
- van der Velde AR, Lexis CPH, Meijers WC, et al. Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction. Clin Chim Acta. 2016; 452: 50–57.
- Seki K, Sanada S, Kudinova AY, et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail. 2009; 2(6): 684–691.
- Dominguez-Rodriguez A, Abreu-Gonzalez P. Clinical implications of elevated serum interleukin-6, soluble CD40 ligand, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in patients with acute ST-segment elevation myocardial infarction. Clin Cardiol. 2009; 32(5): 288.
- Guzel S, Serin O, Guzel EC, et al. Interleukin-33, matrix metalloproteinase-9, and tissue inhibitor [corrected] of matrix metalloproteinase-1 in myocardial infarction. Korean J Intern Med. 2013; 28(2): 165–173.
- Richards AM, Di Somma S, Mueller T. ST2 in stable and unstable ischemic heart diseases. Am J Cardiol. 2015; 115(7 Suppl): 48B–58B.
- Shimpo M, Morrow DA, Weinberg EO, et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004; 109(18): 2186–2190.
- Jenkins WS, Roger VL, Jaffe AS, et al. Prognostic value of soluble ST2 after myocardial infarction: a community perspective. Am J Med. 2017; 130(9): 1112.e9–1112.e15.
- Sabatine MS, Morrow DA, Higgins LJ, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008; 117(15): 1936–1944.
- Dhillon OS, Narayan HK, Quinn PA, et al. Interleukin 33 and ST2 in non-ST-elevation myocardial infarction: comparison with Global Registry of Acute Coronary Events Risk Scoring and NT-proBNP. Am Heart J. 2011; 161(6): 1163–1170.
- Weir RAP, Miller AM, Murphy GEJ, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol. 2010; 55(3): 243–250.
- Ho JE, Yin X, Levy D, et al. Galectin 3 and incident atrial fibrillation in the community. Am Heart J. 2014; 167(5): 729–734.e1.
- Wu XY, Li SN, Wen SN, et al. Plasma galectin-3 predicts clinical outcomes after catheter ablation in persistent atrial fibrillation patients without structural heart disease. Europace. 2015; 17(10): 1541–1547.
- Kornej J, Schmidl J, Ueberham L, et al. Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation. PLoS One. 2015; 10(4): e0123574.
- Chen C, Qu X, Gao Z, et al. Soluble ST2 in patients with nonvalvular atrial fibrillation and prediction of heart failure. Int Heart J. 2018; 59(1): 58–63.
- Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128(16): 1810–1852.
- Coglianese EE, Larson MG, Vasan RS, et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin Chem. 2012; 58(12): 1673–1681.
- Lancellotti P, Dulgheru R, Magne J, et al. Elevated plasma soluble ST2 is associated with heart failure symptoms and outcome in aortic stenosis. PLoS One. 2015; 10(9): e0138940.
- Stundl A, Lünstedt NS, Courtz F, et al. Soluble ST2 for risk stratification and the prediction of mortality in patients undergoing transcatheter aortic valve implantation. Am J Cardiol. 2017; 120(6): 986–993.
- Wojciechowska C, Romuk E, Nowalany-Kozielska E, et al. Serum galectin-3 and ST2 as predictors of unfavorable outcome in stable dilated cardiomyopathy patients. Hellenic J Cardiol. 2017; 58(5): 350–359.
- Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004; 110(19): 3121–3128.
- Stolen CM, Adourian A, Meyer TE, et al. Plasma galectin-3 and heart failure outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy). J Card Fail. 2014; 20(11): 793–799.
- Weir RAP, Miller AM, Murphy GEJ, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol. 2010; 55(3): 243–250.
- Yu L, Ruifrok WPT, Meissner M, et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail. 2013; 6(1): 107–117.